Incorporating Genomic Testing, Advanced Imaging, and Artificial Intelligence for Prostate Cancer

Incorporating Genomic Testing, Advanced Imaging, and Artificial Intelligence for Prostate Cancer into Your Practice (2026) CME Available: https://cme.auanet.org/URL/26DC049ONL LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Have a firm understanding of the research that led to the approval of genomic tests for prostate cancer and the implementation of advanced imaging for prostate cancer. 2. Order appropriate genomic testing and advanced imaging based on a patient's unique clinical situation. 3. State the NCCN guidelines for genomic testing and advanced imaging for prostate cancer. 4. Discern the different prognostic endpoints provided by various genomic tests. 5. Recognize candidates for, and implications of, germline testing for prostate cancer. 6. Appreciate the role artificial intelligence is beginning to play to enhance the precision of pathologic readings, advanced imaging interpretation, and genomic testing. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: Astellas Lantheus Medical Imaging Novartis Pharmaceuticals Corporation Pfizer, Inc